Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
Drug guidance

Enfortumab vedotin in combination with pembrolizumab for untreated locally advanced or metastatic urothelial cancer

Condition

Cancer

Urological

1 July 2026

-

Published on 01 Jul 2026
Last Updated on 01 Jul 2026

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

  • Enfortumab vedotin 20 mg and 30 mg powder for concentrate for solution for infusion, in combination with pembrolizumab, for untreated locally advanced or metastatic urothelial cancer.

Funding status

Enfortumab vedotin 20 mg and 30 mg powder for concentrate for solution for infusion are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 September 2026.

MAF assistance does not apply to pembrolizumab for this indication.

Clinical indication, subsidy class and MediShield Life claims eligibility for enfortumab vedotin are provided in the Annex.

Guidance_Enfortumab vedotin in combination with pembrolizumab for untreated locally advanced or metastatic urothelial cancer (1 Jul 2026) [PDF, 280.62 KB]

Back to top